TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Wall Street projects substantial year-over-year growth for TG Therapeutics (TGTX) in Q3 2025, with expected EPS of $0.24 (+1100%) and revenues of $150.66 million (+79.6%). However, recent analyst sentiment indicates caution, as the consensus EPS estimate has been lowered by 5.81% over 30 days, and a negative Zacks Earnings ESP of -17.36% combined with a Zacks Rank #3 suggests the company is not a strong candidate for an earnings beat. This outlook is mirrored in industry peer Kymera Therapeutics (KYMR), which also faces challenges in predicting an earnings beat despite projected revenue growth.

Analysis

TG Therapeutics (TGTX) is projected to report significant year-over-year growth for Q3 2025, with consensus estimates forecasting an 1100% increase in EPS to $0.24 and a 79.6% rise in revenues to $150.66 million. Despite these robust top-line expectations, recent analyst sentiment indicates a cautious outlook regarding an earnings beat.

Over the last 30 days, the consensus EPS estimate for TGTX has been revised downwards by 5.81%, reflecting a collective reassessment by covering analysts. The company currently holds a negative Zacks Earnings ESP of -17.36%, where the Most Accurate Estimate is lower than the consensus, suggesting analysts have become more bearish on near-term earnings prospects.

This negative ESP, combined with a Zacks Rank #3 (Hold), makes it difficult to conclusively predict an earnings beat, as the model's predictive power is significant only for positive ESP readings. TGTX's historical performance further supports this caution, having beaten consensus EPS estimates only once in the last four quarters, including a -46.88% surprise in the last reported quarter.

The cautious sentiment surrounding TGTX's earnings surprise potential is echoed by industry peer Kymera Therapeutics (KYMR), which also exhibits a negative Earnings ESP (-25.87%) despite strong revenue growth projections. This suggests a broader trend of tempered expectations for earnings beats within the Medical - Biomedical and Genetics industry, even amidst high growth forecasts.

Key Decisions for Investors

• Investors should monitor TGTX's Q3 2025 earnings release and subsequent management commentary closely, as the negative Earnings ESP and historical performance suggest a low probability of an EPS beat.
• Evaluate the sustainability of TGTX's projected revenue growth in light of the recent downward EPS estimate revisions and the company's track record of missing consensus estimates.
• Consider the implications of similar negative Earnings ESPs within the Medical - Biomedical and Genetics industry, as this may indicate broader challenges in exceeding earnings expectations despite strong top-line growth forecasts.